Grace Therapeutics, Inc. (GRCE)
1.87
+0.09
(+5.06%)
USD |
NASDAQ |
Nov 06, 10:23
Grace Therapeutics Enterprise Value : 15.21M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 15.21M |
| November 04, 2026 | 15.70M |
| November 03, 2026 | 16.19M |
| November 02, 2026 | 15.70M |
| October 30, 2026 | 17.82M |
| October 29, 2026 | 17.82M |
| October 28, 2026 | 18.95M |
| October 27, 2026 | 16.68M |
| October 26, 2026 | 15.70M |
| October 23, 2026 | 17.65M |
| October 22, 2026 | 17.41M |
| October 21, 2026 | 18.30M |
| October 20, 2026 | 18.47M |
| October 19, 2026 | 16.84M |
| October 16, 2026 | 17.00M |
| October 15, 2026 | 17.98M |
| October 14, 2026 | 17.00M |
| October 13, 2026 | 18.63M |
| October 12, 2026 | 19.12M |
| October 09, 2026 | 20.09M |
| October 08, 2026 | 19.44M |
| October 07, 2026 | 20.42M |
| October 06, 2026 | 19.85M |
| October 05, 2026 | 19.77M |
| October 02, 2026 | 19.93M |
| Date | Value |
|---|---|
| October 01, 2026 | 19.44M |
| September 30, 2026 | 21.23M |
| September 29, 2026 | 20.58M |
| September 28, 2026 | 20.74M |
| September 25, 2026 | 20.74M |
| September 24, 2026 | 21.40M |
| September 23, 2026 | 20.74M |
| September 22, 2026 | 21.07M |
| September 21, 2026 | 20.42M |
| September 18, 2026 | 20.58M |
| September 17, 2026 | 20.91M |
| September 16, 2026 | 21.07M |
| September 15, 2026 | 22.54M |
| September 14, 2026 | 23.51M |
| September 11, 2026 | 22.37M |
| September 10, 2026 | 23.02M |
| September 09, 2026 | 21.07M |
| September 08, 2026 | 20.74M |
| September 04, 2026 | 20.42M |
| September 03, 2026 | 21.07M |
| September 02, 2026 | 21.07M |
| September 01, 2026 | 20.42M |
| August 31, 2026 | 20.91M |
| August 28, 2026 | 20.74M |
| August 27, 2026 | 21.40M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.834B |
| Corcept Therapeutics, Inc. | 7.472B |
| Veru, Inc. | 12.02M |
| Johnson & Johnson | 682.93B |
| Eli Lilly & Co. | 1.329T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.79M |
| Total Expenses (Quarterly) | 15.79M |
| EPS Diluted (Quarterly) | -0.9143 |
| Earnings Yield | -63.28% |
| Normalized Earnings Yield | -37.22 |